ERBB2 and breast cancer: We found that women with a higher TC (as per 1% increase in TC) were less likely to be diagnosed with basal‐like (P = 1.39 × 10−6) and HER2‐enriched (P = 1.39 × 10−6) surrogate molecular subytpes of breast cancer (P < .05), ER‐negative (P < 1 × 10−3), HER2‐positive (P < .05), lymph‐node positive (P < 1 × 10−3), higher tumor grade (P‐trend < 1 × 10−06) and higher Ki‐67 proliferation status (P < 5 × 10−7) (Table 1).